BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. CLBS ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that management will participate in the following conferences in September:
| 21st Annual Global Investment Conference, Sponsored by H.C. Wainwright | ||
| Date & Time: | Thursday, September 12, 2019 at 12:05 p.m. (EDT) | |
| Presenter: | David J. Mazzo, Ph.D. | |
| Venue: | Lotte New York Palace Hotel in New York, NY | |
| Live Webcast: | wsw.com/webcast/hcw5/clbs/ | |
| Texas Heart Institute: Cardiology Grand Rounds | ||
| Title: | The Microcirculation: Center of the Cardiovascular Regenerative Medicine Universe | |
| Date & Time: | Friday, September 13, 2019 at 12:00 p.m. (CDT) | |
| Presenter: | Douglas W. Losordo, MD, FACC, FAHA Executive Vice President, Global Head of Research and Development, Chief Medical Officer | |
| Venue: | Texas Heart Institute Denton A. Cooley Auditorium | |
| Live Webcast: | Texasheart.org/grandrounds | |
| Investing for Cures 2019 | ||
| Date & Time: | Thursday, September 19, 2019 at 9:55 a.m. (EDT) | |
| Presenter: | David J. Mazzo, Ph.D. | |
| Venue: | Lotte New York Palace Hotel in New York, NY | |
| Cincinnati College of Pharmacy Seminar Series | ||
| Title: | The CD34 Cell: Experimental Evidence in Animals and Humans for Angiogenesis and Ischemic Repair | |
| Date & Time: | Thursday, September 19, 2019 at 5:00 p.m. (EDT) | |
| Presenter: | William K. Sietsema, Ph.D., Vice President, Global Regulatory Affairs | |
| Venue: | University of Cincinnati College of Pharmacy | |
About Caladrius Biosciences
Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, recipient of a RMAT designation in the U.S.A. and for which we are in preparation to commence a Phase 3 clinical trial in no option refractory disabling angina. For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
